Pages that link to "Q57912189"

The following pages link to Early Relapses, Onset of Progression, and Late Outcome in Multiple Sclerosis (Q57912189):

Displaying 27 items.

• Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis (Q24185806) (← links)
• The topographical model of multiple sclerosis: A dynamic visualization of disease course (Q27312133) (← links)
• Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. (Q30234672) (← links)
• Potential role of immunoglobulin replacement therapy on MRI measures in multiple sclerosis: a systematic review (Q31009149) (← links)
• Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients (Q35744057) (← links)
• Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study (Q36071620) (← links)
• Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. (Q38196701) (← links)
• Prognostic indicators in pediatric clinically isolated syndrome (Q38821503) (← links)
• Defining secondary progressive multiple sclerosis (Q38843046) (← links)
• Disability and progression in Afro-descendant patients with multiple sclerosis (Q38985395) (← links)
• Flow cytometric analysis of T cell/monocyte ratio in clinically isolated syndrome identifies patients at risk of rapid disease progression. (Q40749805) (← links)
• Multiple sclerosis: preventing progression and disability in MS-when to treat? (Q44793584) (← links)
• Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis (Q46870849) (← links)
• The tension between early diagnosis and misdiagnosis of multiple sclerosis (Q47800390) (← links)
• Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression (Q48257014) (← links)
• Cost-effectiveness of different strategies for treatment relapsing-remitting multiple sclerosis (Q48858478) (← links)
• The relationship of age with the clinical phenotype in multiple sclerosis (Q48912523) (← links)
• Clinical Course of Multiple Sclerosis (Q49874514) (← links)
• Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. (Q50561840) (← links)
• Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis (Q50581322) (← links)
• ["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy]. (Q53288359) (← links)
• Clinical Presentations and Phenotypic Spectrum of Multiple Sclerosis at a University Hospital in Saudi Arabia. (Q55439494) (← links)
• Onset of secondary progressive phase and long-term evolution of multiple sclerosis (Q57912193) (← links)
• Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions (Q58795499) (← links)
• Mitochondrial Dysfunction and Multiple Sclerosis (Q91982232) (← links)
• Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases (Q92394719) (← links)
• Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials (Q97067414) (← links)